JP2018500878A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500878A5
JP2018500878A5 JP2017523804A JP2017523804A JP2018500878A5 JP 2018500878 A5 JP2018500878 A5 JP 2018500878A5 JP 2017523804 A JP2017523804 A JP 2017523804A JP 2017523804 A JP2017523804 A JP 2017523804A JP 2018500878 A5 JP2018500878 A5 JP 2018500878A5
Authority
JP
Japan
Prior art keywords
glycoprotein
dengue virus
antibody
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500878A (ja
JP6671364B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058610 external-priority patent/WO2016070178A1/en
Publication of JP2018500878A publication Critical patent/JP2018500878A/ja
Publication of JP2018500878A5 publication Critical patent/JP2018500878A5/ja
Application granted granted Critical
Publication of JP6671364B2 publication Critical patent/JP6671364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523804A 2014-11-02 2015-11-02 ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物 Expired - Fee Related JP6671364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074053P 2014-11-02 2014-11-02
US62/074,053 2014-11-02
PCT/US2015/058610 WO2016070178A1 (en) 2014-11-02 2015-11-02 Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development

Publications (3)

Publication Number Publication Date
JP2018500878A JP2018500878A (ja) 2018-01-18
JP2018500878A5 true JP2018500878A5 (enExample) 2018-12-13
JP6671364B2 JP6671364B2 (ja) 2020-03-25

Family

ID=55858450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523804A Expired - Fee Related JP6671364B2 (ja) 2014-11-02 2015-11-02 ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物

Country Status (12)

Country Link
US (2) US10398768B2 (enExample)
EP (1) EP3212672A4 (enExample)
JP (1) JP6671364B2 (enExample)
KR (1) KR20170075775A (enExample)
CN (1) CN107207619A (enExample)
AU (1) AU2015338859A1 (enExample)
BR (1) BR112017008952A2 (enExample)
CA (1) CA2966198A1 (enExample)
MX (1) MX2017005524A (enExample)
MY (1) MY179251A (enExample)
SG (1) SG11201703366RA (enExample)
WO (1) WO2016070178A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10955414B2 (en) 2016-08-01 2021-03-23 Inbios International, Inc. Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens
CN106632620B (zh) * 2016-11-29 2019-08-23 菲鹏生物股份有限公司 登革病毒重组抗原及其制备方法和应用
WO2018187799A1 (en) * 2017-04-07 2018-10-11 The Rockefeller University Compositions and methods related to human neutralizing antibodies to zika and dengue 1 virus
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法
WO2021102363A1 (en) * 2019-11-20 2021-05-27 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
WO2023178310A1 (en) * 2022-03-17 2023-09-21 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same
CN116716322B (zh) * 2023-05-12 2024-05-31 中山大学 一种denv-3全长感染性克隆及其构建方法与应用
WO2024238948A2 (en) * 2023-05-17 2024-11-21 University Of Iowa Research Foundation Dengue virus serotype-specific modulation of t cell responses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
EP2589602B1 (en) * 2006-08-15 2016-04-06 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of dengue virus vaccine components
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
CA2918644A1 (en) * 2013-06-26 2014-12-31 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus vaccines

Similar Documents

Publication Publication Date Title
JP2018500878A5 (enExample)
Fougeroux et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Sun et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
Pimentel et al. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine
Park et al. Analyzing immune responses to varied mRNA and protein vaccine sequences
JP2015524422A5 (enExample)
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
Carignan et al. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine
RU2015155821A (ru) Вакцины против малярии
ZA202104213B (en) Antibodies that neutralize hepatitis b virus and uses thereof
Jiang et al. Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy
NO20090178L (no) Vaksiner for malaria
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
Song et al. Plant‐based, adjuvant‐free, potent multivalent vaccines for avian influenza virus via Lactococcus surface display
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
Davenport et al. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
RU2016133598A (ru) Композиция микобактериального антигена
JP2017526689A5 (enExample)
Zhou et al. An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection
TW202144003A (zh) 包含固定化病毒粒子之疫苗
Abente et al. Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs
JP2016528176A5 (enExample)
WO2018066999A3 (en) Chimeric enterovirus virus-like particles